Healthcare / BiotechnologyKOSDAQ
$6190.00
-350.00 (-5.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-16.7B · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$168.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.5%
↓Gross Margin
41.0%
↓Debt/Equity
0.79
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.5%
FCF CAGR
—
FCF margin
-127.6%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.29B · net income $-17.36B · FCF $-15.68B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.29B | $12.29B | $6.79B | $4.90B | $9.12B |
| Net Income | $-17.36B | $-17.36B | $-20.64B | $-17.91B | $-29.85B |
| EBITDA | $-9.66B | $-9.66B | $-15.70B | $-13.31B | $-27.12B |
| EPS | -640.00 | -640.00 | -799.00 | -734.00 | -1246.00 |
| Gross Margin | 41.0% | 41.0% | 28.7% | 100.0% | 100.0% |
| Operating Margin | -131.3% | -131.3% | -275.3% | -568.1% | -281.2% |
| Net Margin | -141.3% | -141.3% | -303.9% | -365.6% | -327.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.79 | 0.79 | 0.58 | 0.41 | 0.38 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.68B | $-15.68B | $-16.67B | $-38.98B | $-27.33B |
| Returns | |||||
| ROE | -42.5% | -42.5% | -39.3% | -25.6% | -48.9% |
| Valuation | |||||
| P/B | 4.12 | 4.12 | 2.16 | 3.34 | 4.38 |
| Growth & Yield | |||||
| Revenue Growth | 80.9% | 80.9% | 38.7% | -46.3% | — |
| EPS Growth | 19.9% | 19.9% | -8.9% | 41.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-799.00 → -640.00
Residual
+4.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.